Globe Newswire: bioAffinity Technologies Forms Subsidiary to Focus on Targeted Cancer Drug Delivery

bioAffinity Technologies today announced the formation of OncoSelect Therapeutics, LLC, a subsidiary company that will leverage bioAffinity’s proprietary porphyrin-based diagnostic technology to target a variety of cancers for precision treatment.

Read the full story at Globe Newswire

Share This Article!